Insights into the use of biomarkers in calcific aortic valve disease

Journal of Heart Valve Disease

Volumn 19, Issue 4, 2010, Pages 441-452

  Beckmann, Erik ^a   Grau, Juan B ^a   Sainger, Rachana ^a   Poggio, Paolo ^a   Ferrari, Giovanni ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; FETUIN A; GAMMA GLUTAMYLTRANSFERASE; HOMOCYSTEINE; LEPTIN; LOW DENSITY LIPOPROTEIN; N(G),N(G) DIMETHYLARGININE; OSTEOPONTIN; TISSUE PLASMINOGEN ACTIVATOR;

AORTA VALVE STENOSIS; CALCIUM METABOLISM; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE SEVERITY; HUMAN; PHOSPHATE METABOLISM; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SOFT TISSUE CALCIFICATION; ANIMAL; AORTA VALVE; AORTIC VALVE STENOSIS; BLOOD; CALCINOSIS; HEART VALVE DISEASES; HEART VALVE REPLACEMENT; METABOLISM; PATHOLOGY; PREDICTIVE VALUE; SCLEROSIS; SEVERITY OF ILLNESS INDEX;

ANIMALS; AORTIC VALVE; AORTIC VALVE STENOSIS; BIOLOGICAL MARKERS; CALCINOSIS; DISEASE PROGRESSION; HEART VALVE DISEASES; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SCLEROSIS; SEVERITY OF ILLNESS INDEX;

EID: 77956016697     PISSN: 09668519     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: Pathogenesis, disease progression, and treatment strategies. Circulation 2005;111:3316-3326
2. Goldbarg SH, Elmariah S, Miller MA, Fuster V. Insights into degenerative aortic valve disease. J Am Coll Cardiol 2007;50:1205-1213
3. Bach DS, Radeva JI, Birnbaum HG, Fournier AA, Tuttle EG. Prevalence, referral patterns, testing, and surgery in aortic valve disease: Leaving women and elderly patients behind? J Heart Valve Dis 2007;16:362-369
4. Cowell SJ, Newby DE, Boon NA, Elder AT. Calcific aortic stenosis: Same old story? Age Ageing 2004;33:538-544
5. Thom T, Haase N, Rosamon W, et al. Heart disease and stroke statistics - 2006 update. Circulation 2006;113:e85-e151
6. Northrup WF, III, Dubois KA, Kshettry VR, Teskey JM, Nicoloff DM. Trends in aortic valve surgery in a large multi-surgeon, multi-hospital practice, 1979-1999. J Heart Valve Dis 2002;11:768-778
7. Balmer C, Beghetti M, Fasnacht M, Friedli B, Arbenz U. Balloon aortic valvoplasty in paediatric patients: Progressive aortic regurgitation is common. Heart 2004;90:77-81 (Pubitemid 38064551)
8. Perin MA, Brito FS, Jr., Almeida BO, et al. Percutaneous aortic valve replacement for the treatment of aortic stenosis: Early experience in Brazil. Arq Bras Cardiol 2009;93:299-306
9. Webb JG, Chandavimol M, Thompson CR, et al. Percutaneous aortic valve implantation retrograde from the femoral artery. Circulation 2006;113:842-850
10. Wang A, Harrison JK, Bashore TM. Balloon aortic valvuloplasty. Prog Cardiovasc Dis 1997;40:27-36
11. Parolari A, Loardi C, Mussoni L, et al. Nonrheumatic calcific aortic stenosis: An overview from basic science to pharmacological prevention. Eur J Cardiothorac Surg 2009;35:493-504
12. O'Brien KD. Pathogenesis of calcific aortic valve disease: A disease process comes of age (and a good deal more). Arterioscler Thromb Vasc Biol 2006;26:1721-1728
13. Otto CM, O'Brien KD. Why is there discordance between calcific aortic stenosis and coronary artery disease? Heart 2001;85:601-602
14. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;339:572-575
15. Ngo DT, Heresztyn T, Mishra K, Marwick TH, Horowitz JD. Aortic stenosis is associated with elevated plasma levels of asymmetric dimethylarginine (ADMA). Nitric Oxide 2007;16:197-201 (Pubitemid 46149393)
16. Ngo DT, Sverdlov AL, Willoughby SR, et al. Determinants of occurrence of aortic sclerosis in an aging population. J Am Coll Cardiol Cardiovasc Imaging 2009;2:919-927
17. van Guldener C, Nanayakkara PW, Stehouwer CD. Homocysteine and asymmetric dimethylarginine (ADMA): Biochemically linked but differently related to vascular disease in chronic kidney disease. Clin Chem Lab Med 2007;45:1683-1687
18. Novaro GM, Aronow HD, Mayer-Sabik E, et al. Plasma homocysteine and calcific aortic valve disease. Heart 2004;90:802-803
19. Gunduz H, Arinc H, Tamer A, et al. The relation between homocysteine and calcific aortic valve stenosis. Cardiology 2005;103:207-211
20. Perler B. Thrombolytic therapies: The current state of affairs. J Endovasc Ther 2005;12:224-232
21. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995;332:635-641
22. Glader CA, Birgander LS, Söderberg S, et al. Lipoprotein(a), Chlamydia pneumoniae, leptin and tissue plasminogen activator as risk markers for valvular aortic stenosis. Eur Heart J 2003;24:198-208
23. Mallika V, Goswami B, Rajappa M. Atherosclerosis pathophysiology and the role of novel risk factors: A clinicobiochemical perspective. Angiology 2007;58:513-522 (Pubitemid 47622823)
24. Wilmshurst PT, Stevenson RN, Griffiths H, Lord JR. A case-control investigation of the relation between hyperlipidaemia and calcific aortic valve stenosis. Heart 1997;78:475-479
25. Stewart BF, Siscovick D, Lind BK, et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol 1997;29:630-634
26. Boon A, Cheriex E, Lodder J, Kessels F. Cardiac valve calcification: Characteristics of patients with calcification of the mitral annulus or aortic valve. Heart 1997;78:472-474 (Pubitemid 27515107)
27. Rabuş MB, Kayalar N, Sareyyüpoi lu B, Erkin A, Kirali K, Yakut C. Hypercholesterolemia association with aortic stenosis of various etiologies. J Card Surg 2009;24:146-150
28. Hoagland PM, Cook EF, Flatley M, Walker C, Goldman L. Case-control analysis of risk factors for presence of aortic stenosis in adults (age 50 years or older). Am J Cardiol 1985;55:744-747
29. Mohler ER, Sheridan MJ, Nichols R, Harvey WP, Waller BF. Development and progression of aortic valve stenosis: Atherosclerosis risk factors - a causal relationship? A clinical morphologic study. Clin Cardiol 1991;14:995-999
30. Peter M, Hoffmann A, Parker C, Lüscher T, Burckhardt D. Progression of aortic stenosis. Role of age and concomitant coronary artery disease. Chest 1993;103:1715-1719
31. Bahler RC, Desser DR, Finkelhor RS, Brener SJ, Youssefi M. Factors leading to progression of valvular aortic stenosis. Am J Cardiol 1999;84:1044-1048 (Pubitemid 29505373)
32. Côté C, Pibarot P, Després JP, et al. Association between circulating oxidised low-density lipoprotein and fibrocalcific remodelling of the aortic valve in aortic stenosis. Heart 2008;94:1175-1180
33. Messika-Zeitoun D, Bielak LF, Peyser PA, et al. Aortic valve calcification: Determinants and progression in the population. Arterioscler Thromb Vasc Biol 2007;27:642-648
34. Aronow WS, Ahn C, Kronzon I, Goldman ME. Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol 2001;88:693-695 (Pubitemid 32831111)
35. Palta S, Pai AM, Gill KS, Pai RG. New insights into the progression of aortic stenosis: Implications for secondary prevention. Circulation 2000;101:2497-2502
36. Nassimiha D, Aronow WS, Ahn C, Goldman ME. Association of coronary risk factors with progression of valvular aortic stenosis in older persons. Am J Cardiol 2001;87:1313-1314 (Pubitemid 32493881)
37. Bellamy MF, Pellikka PA, Klarich KW, Tajik AJ, Enriquez-Sarano M. Association of cholesterol levels, hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community. J Am Coll Cardiol 2002;40:1723-1730
38. Cowell SJ, Newby DE, Prescott RJ, et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005;352:2389-2397
39. Rosseo AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008;359:1343-1356
40. Chan KL, Teo K, Dumesnil JG, et al. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: Results of the aortic stenosis progression observation. Measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation 2010;1213:306-314
41. Rosenhek R, Binder T, Porenta G, et al. Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med 2000;343:611-617 (Pubitemid 30659472)
42. Lloyd-Jones D, Adams R, Carnethon M. Heart disease and stroke statistics - 2009 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009;119:e21-e181
43. Brennan AM, Mantzoros CS. Drug insight: The role of leptin in human physiology and pathophysiology - emerging clinical applications. Nat Clin Pract Endocrinol Metab 2006;2:318-327
44. Söderberg S, Ahrén B, Jansson JH, et al. Leptin is associated with increased risk of myocardial infarction. J Intern Med 1999;246:409-418
45. Hirschfield GM, Pepys MB. C-reactive protein and cardiovascular disease: New insights from an old molecule. Q J Med 2003;96:793-807 (Pubitemid 37369294)
46. Galante A, Pietroiusti A, Vellini M, et al. C-reactive protein is increased in patients with degenerative aortic valvular stenosis. J Am Coll Cardiol 2001;38:1078-1082
47. Gunduz H, Arinc H, Tamer A, et al. The relation between homocysteine and calcific aortic valve stenosis. Cardiology 2005;103:207-211
48. Imai K, Okura H, Kume T, et al. C-Reactive protein predicts severity, progression, and prognosis of asymptomatic aortic valve stenosis. Am Heart J 2008;156:713-718
49. Agmon Y, Khandheria BK, Jamil Tajik A, et al. Inflammation, infection, and aortic valve sclerosis: Insights from the Olmsted County (Minnesota) population. Atherosclerosis 2004;174:337-342
50. Jeevanantham V, Singh N, Izuora K, D'Souza JP, Hsi DH. Correlation of high sensitivity C-reactive protein and calcific aortic valve disease. Mayo Clin Proc 2007;82:171-174 (Pubitemid 46198475)
51. Sánchez PL, Santos JL, Kaski JC, et al. Relation of circulating C-reactive protein to progression of aortic valve stenosis. Am J Cardiol 2006;97:90-93
52. Novaro GM, Katz R, Aviles RJ, et al. Clinical factors, but not C-reactive protein, predict progression of calcific aortic-valve disease: The Cardiovascular Health Study. J Am Coll Cardiol 2007;50:1992-1998
53. Price PA, Lim JE. The inhibition of calcium phosphate precipitation by fetuin is accompanied by the formation of a fetuin-mineral complex. J Biol Chem 2003;278:22144-22152
54. Wang AY, Woo J, Lam CW, et al. Associations of serum fetuin-A with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients. Nephrol Dial Transplant 2005;20:1676-1685
55. Ix JH, Chertow GM, Shlipak MG, Brandenburg VM, Ketteler M, Whooley M. Association of fetuin-A with mitral annular calcification and aortic stenosis among persons with coronary heart disease: Data from the Heart and Soul Study. Circulation 2007;115:2533-2539
56. Koos R, Brandenburg V, Mahnken AH, et al. Association of fetuin-A levels with the progression of aortic valve calcification in non-dialyzed patients. Eur Heart J 2009;30:2054-2061
57. O'Neill WC. The fallacy of the calcium-phosphorus product. Kidney Int 2007;72:792-796
58. Straumann E, Meyer B, Misteli M, Blumberg A, Jenzer HR. Aortic and mitral valve disease in patients with end-stage renal failure on long-term haemodialysis. Br Heart J 1992;67:236-239
59. Mills WR, Einstadter D, Finkelhor RS. Relation of calcium-phosphorus product to the severity of aortic stenosis in patients with normal renal function. Am J Cardiol 2004;94:1196-1198 (Pubitemid 39424231)
60. Cho HJ, Cho HJ, Kim HS. Osteopontin: A multifunctional protein at the crossroads of inflammation, atherosclerosis, and vascular calcification. Curr Atheroscler Rep 2009;11:206-213
61. Yu PJ, Skolnick A, Ferrari G, et al. Correlation between plasma osteopontin levels and aortic valve calcification: Potential insights into the pathogenesis of aortic valve calcification and stenosis. J Thorac Cardiovasc Surg 2009;138:196-199
62. Weber GF, Zawaideh S, Hikita S, Kumar VA, Cantor H, Ashkar S. Phosphorylation-dependent interaction of osteopontin with its receptors regulates macrophage migration and activation. J Leukoc Biol 2002;72:752-761
63. Whitfield JB. Gamma glutamyl transferase. Crit Rev Clin Lab Sci 2001;38:263-355
64. Wannamethee G, Ebrahim S, Shaper AG. Gamma-glutamyltransferase: Determinants and association with mortality from ischemic heart disease and all causes. Am J Epidemiol 1995;142:699-708
65. Bozbas H, Yildirir A, Demir O, et al. Serum gamma-glutamyltransferase activity is increased in patients with calcific aortic valve stenosis. J Heart Valve Dis 2008;17:371-375
66. Luchner A, Stevens TL, Borgeson DD, et al. Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. Am J Physiol 1998;274:H1684-H1689
67. Rodeheffer RJ. Measuring plasma B-type natriuretic peptide in heart failure: Good to go in 2004? J Am Coll Cardiol 2004;44:740-749 (Pubitemid 39099566)
68. Qi W, Mathisen P, Kjekshus J, et al. Natriuretic peptides in patients with aortic stenosis. Am Heart J 2001;142:725-732
69. Talwar S, Downie PF, Squire IB, Davies JE, Barnett DB, Ng LL. Plasma N-terminal pro BNP and cardiotrophin-1 are elevated in aortic stenosis. Eur J Heart Fail 2001;3:15-19
70. Prasad N, Bridges AB, Lang CC, et al. Brain natriuretic peptide concentrations in patients with aortic stenosis. Am Heart J 1997;133:477-479
71. Lim P, Monin JL, Monchi M, et al. Predictors of outcome in patients with severe aortic stenosis and normal left ventricular function: Role of B-type natriuretic peptide. Eur Heart J 2004;25:2048-2053
72. Weber M, Arnold R, Rau M, et al. Relation of N-terminal pro-B-type natriuretic peptide to severity of valvular aortic stenosis. Am J Cardiol 2004;94:740-745 (Pubitemid 39221490)
73. Gerber IL, Stewart RA, Legget ME, et al. Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis. Circulation 2003;107:1884-1890
74. Bergler-Klein J, Klaar U, Heger M, et al. Natriuretic peptides predict symptom-free survival and postoperative outcome in severe aortic stenosis. Circulation 2004;109:2302-2308
75. Weber M, Arnold R, Rau M, et al. Relation of N-terminal pro B-type natriuretic peptide to progression of aortic valve disease. Eur Heart J 2005;26:1023-1030
76. Gerber IL, Legget ME, West TM, Richards AM, Stewart RA. Usefulness of serial measurement of N-terminal pro-brain natriuretic peptide plasma levels in asymptomatic patients with aortic stenosis to predict symptomatic deterioration. Am J Cardiol 2005;95:898-901
77. Weber M, Hausen M, Arnold R, et al. Prognostic value of N-terminal pro-B-type natriuretic peptide for conservatively and surgically treated patients with aortic valve stenosis. Heart 2006;92:1639-1644
78. Pedrazzini GB, Masson S, Latini R, et al. Comparison of brain natriuretic peptide plasma levels versus logistic EuroSCORE in predicting inhospital and late postoperative mortality in patients undergoing aortic valve replacement for symptomatic aortic stenosis. Am J Cardiol 2008;102:749-754
79. Bergler-Klein J, Mundigler G, Pibarot P, et al. B-type natriuretic peptide in low-flow, low-gradient aortic stenosis: Relationship to hemodynamics and clinical outcome. Results from the Multicenter Truly or Pseudo-Severe Aortic Stenosis (TOPAS) study. Circulation 2007;115:28;48-55
80. Nessmith MG, Fukuta H, Brucks S, Little WC. Usefulness of an elevated B-type natriuretic peptide in predicting survival in patients with aortic stenosis treated without surgery. Am J Cardiol 2005;96:1445-1448 (Pubitemid 41566630)
81. Rajamannan NM, Bonow RO, Rahimtoola SH. Calcific aortic stenosis: An update. Nat Clin Pract Cardiovasc Med 2007;4:254-262
82. Frank S, Johnson A, Ross J, Jr. Natural history of valvular aortic stenosis. Br Heart J 1973;35:41-46